FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008175795> ?p ?o ?g. }

• W3008175795 endingPage "S221" @default.
• W3008175795 startingPage "S221" @default.
• W3008175795 abstract "Metastatic soft tissue sarcomas are associated with poor outcomes. Many patients undergo multiple treatment modalities for disease control. Of particular interest is the combination of cryoablation and immunotherapy on the progression of metastatic disease. This study aims to assess the effect of cryoablation on non-target pulmonary lesions in immunotherapy patients with metastatic leiomyosarcoma or liposarcoma. Single-center retrospective analysis was performed on 16 patients with leiomyosarcoma or liposarcoma who underwent cryoablation of lung metastases between 2014-2018. Twelve patients were identified who were receiving immunotherapy at time of ablation; these patients had shown disease progression on chemotherapy. Greatest single dimension measurements were performed on cryoablated metastases and up to three non-target lesions both before and after ablation. Linear regression analysis was performed to evaluate growth rates of each lesion before and after ablation. Twelve patients with leiomyosarcoma (N = 9) or liposarcoma (N = 3) underwent cryoablation of lung metastases while undergoing immunotherapy. Average age was 64 years, and 75% of patients were female. Average time between CT or PET-CT scans was 2.7 months. All patients remained on immunotherapy after cryoablation. Growth rate of targeted metastases prior to ablation was 1.39 mm/30 days. No growth of targeted metastases was seen after ablation. Growth rate for non-target lesions prior to ablation was 0.54 mm/30 days, while growth rate after ablation was 0.47 mm/30 days (P = 0.66). All non-target lesions continued to progress after ablation. Three patients developed pneumothorax requiring chest tube but no major complications were observed. Cryoablation of pulmonary metastases in immunotherapy patients with liposarcoma or leiomyosarcoma is technically feasible with high success rate of treated metastases without major complications. Though a mild difference in growth rate was observed in growth rates of non-target lesions before and after cryoablation, no statistical significance was reached. Additional data will be needed to determine if cryoablation slows growth significantly for non-target lesions." @default.
• W3008175795 created "2020-03-06" @default.
• W3008175795 creator A5004191136 @default.
• W3008175795 creator A5022982759 @default.
• W3008175795 creator A5053601743 @default.
• W3008175795 creator A5055110735 @default.
• W3008175795 creator A5082200523 @default.
• W3008175795 date "2020-03-01" @default.
• W3008175795 modified "2023-09-26" @default.
• W3008175795 title "Abstract No. 503 Effects of cryoablation with immunotherapy on patients with metastatic soft tissue sarcoma" @default.
• W3008175795 doi "https://doi.org/10.1016/j.jvir.2019.12.564" @default.
• W3008175795 hasPublicationYear "2020" @default.
• W3008175795 type Work @default.
• W3008175795 sameAs 3008175795 @default.
• W3008175795 citedByCount "0" @default.
• W3008175795 crossrefType "journal-article" @default.
• W3008175795 hasAuthorship W3008175795A5004191136 @default.
• W3008175795 hasAuthorship W3008175795A5022982759 @default.
• W3008175795 hasAuthorship W3008175795A5053601743 @default.
• W3008175795 hasAuthorship W3008175795A5055110735 @default.
• W3008175795 hasAuthorship W3008175795A5082200523 @default.
• W3008175795 hasBestOaLocation W30081757951 @default.
• W3008175795 hasConcept C126322002 @default.
• W3008175795 hasConcept C126838900 @default.
• W3008175795 hasConcept C136948725 @default.
• W3008175795 hasConcept C141071460 @default.
• W3008175795 hasConcept C142724271 @default.
• W3008175795 hasConcept C2777532014 @default.
• W3008175795 hasConcept C2777628079 @default.
• W3008175795 hasConcept C2778256501 @default.
• W3008175795 hasConcept C2778629024 @default.
• W3008175795 hasConcept C2778902805 @default.
• W3008175795 hasConcept C2779568860 @default.
• W3008175795 hasConcept C71924100 @default.
• W3008175795 hasConceptScore W3008175795C126322002 @default.
• W3008175795 hasConceptScore W3008175795C126838900 @default.
• W3008175795 hasConceptScore W3008175795C136948725 @default.
• W3008175795 hasConceptScore W3008175795C141071460 @default.
• W3008175795 hasConceptScore W3008175795C142724271 @default.
• W3008175795 hasConceptScore W3008175795C2777532014 @default.
• W3008175795 hasConceptScore W3008175795C2777628079 @default.
• W3008175795 hasConceptScore W3008175795C2778256501 @default.
• W3008175795 hasConceptScore W3008175795C2778629024 @default.
• W3008175795 hasConceptScore W3008175795C2778902805 @default.
• W3008175795 hasConceptScore W3008175795C2779568860 @default.
• W3008175795 hasConceptScore W3008175795C71924100 @default.
• W3008175795 hasIssue "3" @default.
• W3008175795 hasLocation W30081757951 @default.
• W3008175795 hasOpenAccess W3008175795 @default.
• W3008175795 hasPrimaryLocation W30081757951 @default.
• W3008175795 hasRelatedWork W1493414140 @default.
• W3008175795 hasRelatedWork W1964112796 @default.
• W3008175795 hasRelatedWork W2037908913 @default.
• W3008175795 hasRelatedWork W2080554012 @default.
• W3008175795 hasRelatedWork W2398316371 @default.
• W3008175795 hasRelatedWork W2560779102 @default.
• W3008175795 hasRelatedWork W2803808327 @default.
• W3008175795 hasRelatedWork W3202572366 @default.
• W3008175795 hasRelatedWork W322136363 @default.
• W3008175795 hasRelatedWork W4225305779 @default.
• W3008175795 hasVolume "31" @default.
• W3008175795 isParatext "false" @default.
• W3008175795 isRetracted "false" @default.
• W3008175795 magId "3008175795" @default.
• W3008175795 workType "article" @default.